Digg
Del.icio.us
Newsvine 
Facebook
StumbleuponCSL, the world's second-largest plasma producer may have its planned $US3.1 billion acquisition of Talecris blocked by US trade authorities as US FTC staff oppose the deal and recommend that legal action be taken to prevent the merger.
The acquisition of the specialist plasma producer will result in a cut the number of producers in the US, giving existing players more pricing power if gone ahead with the merger.
If the deal is eventually blocked CSL is likely to return the money raised ($36.75 a share) back to the shareholders in some way. If the deal is blocked, CSL will also have to pay a break fee of $US75 million ($96 million) to the private equity vendors Cerberus and Ampersand.
But first it must await the final FTC decision then decide whether to fight the decision in court and lastly it may utilise the money for other purposes.
CSL managing director Brian McNamee met with FTC officials last Friday to argue for the transaction and present potential remedies to address antitrust concerns.
CSL proposed last August to buy Talecris to boost its share of the $US15 billion-a-year global plasma therapeutics market.
Shares of CSL were down 2.1 per cent at $30.23 in early trading in a firmer market overall. The benchmark S&P/ASX 200 index was 0.5 per cent higher according to figures in the Australian.
The one-time fiancée of cricketer Michael Clarke underwent a screen test for a job as an entertainment reporter at Bigpond TV. Unfortunately for ...
Continuing a trend in Queensland's residential property market, the number of sales of units and townhouses reduced markedly during the tail end ...
Two Australian school teachers from Warwick State High School have become the subject of controversy after posting raunchy photos of themselves i...
© 2010 The Ibtimes Company. All Rights Reserved.
Partners 
EMAIL
PRINT
RSS
SHARE
